4893.T
Noile-Immune Biotech Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 87.00
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | 3.0M | 5.0M | 7.0M | 316.0M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Operating Expenses | ||||
| R&D Expense | — | — | — | — |
| SG&A Expense | — | — | — | — |
| General & Admin Expense | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | — | — | — | — |
| Cost and Expenses | 559.0M | 802.0M | 1.1B | 1.1B |
| Operating Income (EBIT) | (758.0M) | (797.0M) | (1.1B) | (775.0M) |
| Non-Operating | ||||
| Interest Income | 8.2M | 6.4M | 560.0K | 44.0K |
| Interest Expense | — | — | — | — |
| Net Interest Income | — | — | — | — |
| Other Non-Op Income/Expense | 3.7M | 6.1M | 107.1M | (352.2M) |
| Non-Operating Income (excl Interest) | 45.0M | 12.0K | 107.0M | 6.0K |
| EBT (Pre-Tax Income) | (704.8M) | (791.1M) | (962.0M) | (1.1B) |
| Income Tax Expense | 2.1M | 2.4M | 2.4M | 2.4M |
| Bottom Line | ||||
| Net Income | (706.0M) | (793.0M) | (964.0M) | (1.1B) |
| Earnings from Cont. Ops | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (706.0M) | (793.0M) | (964.0M) | (1.1B) |
| Per Share | ||||
| Basic EPS | (¥16) | (¥18) | (¥22) | (¥27) |
| Diluted EPS | (¥16) | — | — | — |
| Revenue Per Share | ¥0 | ¥0 | ¥0 | ¥8 |
| Shares | ||||
| Basic Shares Outstanding | 43.3M | 43.3M | 43.3M | 41.5M |
| Diluted Shares Outstanding | — | — | — | — |
| Profitability Metrics | ||||
| EBITDA | — | — | — | — |
| D&A | — | — | — | — |
| EBIT | (758.0M) | (797.0M) | (1.1B) | (775.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026